Calls for papers
-
Cipla has announced the launch of a mobile app called “My Breathefree,” which is intended to serve as a “virtual caregiver” for asthma patients in India. The app includes video demonstrations of correct use for… Read more . . .
-
Discovery Laboratories has announced the initiation of a Phase 2b trial of Aerosurf aerosolized KL4 surfactant to treat respiratory distress syndrome (RDS) in premature infants. The trial, which is expected to enroll up to 250… Read more . . .
-
Skyepharma has announced a partnership agreement with Mundipharma for global development and commercialization of Skyepharma’s SKP-2076 ICS/LABA/LAMA fixed dose combination MDI. Mundipharma, which already markets Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI in Europe and a… Read more . . .
-
GlaxoSmithKline has recalled two lots of Ventolin HFA metered dose inhalers totaling 128,704 inhalers, according to an FDA enforcement report. The company initiated the voluntary recall on December 3, 2015 due to concerns about insufficient… Read more . . .
-
Welcoming over 600 attendees to the Edinburgh International Conference Centre, conference chair Gary Pitcairn opened the meeting on December 9, 2015 by noting the 20% increase in attendance from DDL 25 and suggesting that next… Read more . . .
-
The FDA has granted orphan drug designation to Neurelis’s lead product, NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients, the company said. Biotie paid $1 million for an option to… Read more . . .
-
Alexza Pharmaceuticals has announced interim results from a Phase 2a study of AZ-002 inhaled alprazolam in epilepsy patients. Dose-related decreases in mean standardized photosensivity range (SPR), the study’s primary endpoint, were noted 2 minutes post… Read more . . .
-
A study published online in the journal Diabetes Care on December 17, 2015 demonstrated non-inferiority of intranasal glucagon to intramuscular glucagon for the treatment of insulin-induced hypoglycemia in type 1 diabetes patients. The study found… Read more . . .
-
After the arrest of its CEO, Martin Shkreli, on securities fraud charges, Turing Pharmaceuticals has announced Shkreli’s resignation and the appointment of Ron Tilles as Interim CEO. Tilles has chaired Turing’s board of directors since… Read more . . .
-
AstraZeneca has announced that it will acquire Takeda’s respiratory line for $575 million. According to the company, about 200 Takeda employees will transfer to AstraZeneca as part of the deal. The company is citing the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA